PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18045297-3	2007	RESULTS: Patients on montelukast therapy for 8 weeks had significantly decreased levels of eNO and plasma MMP-9, which were associated with improved symptoms and enhanced peak expiratory flow but not significantly associated with increased level of tissue inhibitor metalloproteinase-1 (TIMP-1).	montelukast	21-32	matrix metallopeptidase 9	Homo sapiens	106-111	
18045297-0	2007	Suppression of plasma matrix metalloproteinase-9 following montelukast treatment in childhood asthma.	montelukast	59-70	matrix metallopeptidase 9	Homo sapiens	22-48	
28098359-6	2017	MMP-9 expression and activity were reduced by a TNFalpha blocking antibody adalimumab and a cysteinyl leukotriene receptor 1 (CysLTR1, the receptor for LTD4 ) antagonist montelukast.	montelukast	170-181	matrix metallopeptidase 9	Homo sapiens	0-5	
16815146-11	2006	Montelukast, but neither MK-0591 nor LTD(4), reduced the expression of urokinase plasminogen activator receptor and the secretion of MMP-9 and increased total cellular activity of urokinase plasminogen activator and the expression of plasminogen activator inhibitor 2 mRNA.	montelukast	0-11	matrix metallopeptidase 9	Homo sapiens	133-138	
31313075-8	2019	On the other hand, montelukast suppressed the expression and production of matrix metalloproteinases (MMPs) and cytokines including MMP-2, MMP-9, interleukin 1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), and interleukin 6 (IL-6).	montelukast	19-30	matrix metallopeptidase 9	Homo sapiens	139-144	
29432192-4	2018	Analysis of tissue extracts revealed that montelukast reduces the levels of matrix metalloproteinase-9 (MMP-9) and macrophage inflammatory protein-1alpha (MIP-1alpha) in the aortic wall.	montelukast	42-53	matrix metallopeptidase 9	Homo sapiens	76-102	
29432192-4	2018	Analysis of tissue extracts revealed that montelukast reduces the levels of matrix metalloproteinase-9 (MMP-9) and macrophage inflammatory protein-1alpha (MIP-1alpha) in the aortic wall.	montelukast	42-53	matrix metallopeptidase 9	Homo sapiens	104-109	
27657514-2	2016	OBJECTIVES: To evaluate the effect of montelukast treatment on markers of airway inflammation and remodeling in children with mild asthma and to evaluate if the administration of montelukast to children with mild asthma could inhibit the release of matrix metallopeptidase 9, matrix metallopeptidase 12, tissue inhibitor of metalloproteinase 1, transforming growth factor beta 1, C-peptide terminal procollagen type (PICP), and eosinophils count, which are markers of inflammation and remodeling in induced sputum.	montelukast	179-190	matrix metallopeptidase 9	Homo sapiens	249-274